Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

IPO Calendar. M&A Calendar. SPAC Calendar. Stock Split Calendar. Trade Ideas. ... The stock price for Passage Bio (NASDAQ: PASG) is $0.3232 last updated June 27, 2025 at 7:01 PM EDT. Q.

As at September 2024, Passage Bio had cash of US$85m and no debt. Importantly, its cash burn was US$59m over the trailing twelve months. Therefore, from September 2024 it had roughly 17 months of ...

(RTTNews) - Passage Bio (PASG), a clinical-stage genetic medicines company, on Friday announced positive interim data from its ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the ...

Nasdaq's IPO Process; ETF Listings; Nasdaq-100 Index Options; Derivatives Academy; Drive Growth with Insights ... (RTTNews) - PASSAGE BIO, INC. (PASG) revealed Loss for full year of -$64.77 million.

In March 2024, Passage Bio had US$105m in cash, and was debt-free. Looking at the last year, the company burnt through US$75m. That means it had a cash runway of around 17 months as of March 2024.

Find the latest analyst research, reports, and ratings for Passage Bio, Inc. Common Stock (PASG) at Nasdaq.com.

Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline ...

Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition ...

On September 19, 2024, Orbimed Advisors LLC, a prominent investment firm, executed a significant transaction involving the shares of Passage Bio Inc (NASDAQ:PASG). Despite this reduction, Orbimed ...

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on June 24, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...